Human peroxiredoxin 6 is essential for malaria parasites and provides a host-based drug target

Cell Rep. 2022 Jun 14;39(11):110923. doi: 10.1016/j.celrep.2022.110923.

Abstract

The uptake and digestion of host hemoglobin by malaria parasites during blood-stage growth leads to significant oxidative damage of membrane lipids. Repair of lipid peroxidation damage is crucial for parasite survival. Here, we demonstrate that Plasmodium falciparum imports a host antioxidant enzyme, peroxiredoxin 6 (PRDX6), during hemoglobin uptake from the red blood cell cytosol. PRDX6 is a lipid-peroxidation repair enzyme with phospholipase A2 (PLA2) activity. Inhibition of PRDX6 with a PLA2 inhibitor, Darapladib, increases lipid-peroxidation damage in the parasite and disrupts transport of hemoglobin-containing vesicles to the food vacuole, causing parasite death. Furthermore, inhibition of PRDX6 synergistically reduces the survival of artemisinin-resistant parasites following co-treatment of parasite cultures with artemisinin and Darapladib. Thus, PRDX6 is a host-derived drug target for development of antimalarial drugs that could help overcome artemisinin resistance.

Keywords: CP: Metabolism; CP: Microbiology; PRDX6; Plasmodium falciparum; artemisinin; endocytosis; hemoglobin; host cell cytosol uptake; lipid peroxidation; malaria; molecular parasitology; oxidative stress.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antimalarials* / pharmacology
  • Artemisinins* / metabolism
  • Artemisinins* / pharmacology
  • Benzaldehydes / pharmacology
  • Drug Resistance
  • Hemoglobins / metabolism
  • Humans
  • Lipids
  • Malaria* / drug therapy
  • Malaria, Falciparum* / drug therapy
  • Malaria, Falciparum* / parasitology
  • Mice
  • Oximes / pharmacology
  • Peroxiredoxin VI* / immunology
  • Peroxiredoxin VI* / metabolism
  • Plasmodium falciparum

Substances

  • Antimalarials
  • Artemisinins
  • Benzaldehydes
  • Hemoglobins
  • Lipids
  • Oximes
  • Peroxiredoxin VI
  • darapladib